Sergey Nivens / Shutterstock.com
A recent decision in Canada means defendants in patent infringement cases can raise the non-infringing alternative defence in response to damages claims. Mark Biernacki and Cameron Weir of Smart & Biggar/Fetherstonhaugh considers its potential impact on litigation between drugs companies.
On July 23, 2015, in Apotex v Merck & Co, Canada’s Federal Court of Appeal found for the first time that the availability to an infringer of a non-infringing alternative (NIA) is a relevant consideration when calculating damages for patent infringement. This is a significant legal development.
Historically, the availability of NIAs in Canada was only relevant in an accounting of profits—an infrequently used equitable remedy that seeks to disgorge an infringer’s unjustly earned profits. Now one can expect defendants in patent infringement disputes to raise the availability of NIAs in response to claims for damages.
However, the test set out by the appeal court requires that the infringer establishes that it had a NIA, that it both “could and would” have used it absent infringement, and that such NIA would have reduced the plaintiff’s sales. This is anticipated to be a difficult test to meet.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Apotex Inc. v. Merck & Co; NIA; Apotex; Mevacor; patent; patent infringement;